Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 4, 1997, Pages 391-402

  Wehmeier, Artur ^a   Südhoff, Thomas ^a   Meierkord, Frank ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bleeding; Essential thrombocythemia; Myeloproliferative disorders; Polycythemia vera; Thrombosis

Indexed keywords

BLEEDING; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SIZE; CELL ULTRASTRUCTURE; DISEASE ASSOCIATION; HEMATOPOIESIS; HUMAN; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0030748322     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996114     Document Type: Review

References (156)

1. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 6:372-375, 1951.
2. Glasser K, K Walker: Transitions among the myeloproliferative disorders. Ann Intern Med 71:285-306, 1969.
3. Michiels JJ, ME Prins, A Hagermeijer, P Brederoo, Jvd Meulen, HHDM van Vliet, J Abels: Philadelphia chromosome-positive thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 88:645-652, 1987.
4. Ward HP, MH Block: The natural hislory of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndromes. Medicine 50:357-419, 1971.
5. Berlin NI: Diagnosis and classification of the polycythemias. Semin Hematol 12:339-351, 1975.
6. Murphy S, H Iland, D Rosenthal, J Laszlo: Essential thromboeythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 23:177-182, 1986.
7. Thiele J, G Schneider, B Hoeppner, S Wienholt, R Zankovich, R Fischer: Histomorphometry of hone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis - Features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A 413:407-417, 1988.
8. Peterson P, JT Ellis: The bone marrow in polycythemia vera. In: Wasserman LR, PD Berk, NI Berlin (eds): Polycythemia Vera and the Myeloproliferative Disorders. Saunders, Philadelphia, 1995, pp 31-53.
9. Buhr T, A Georgii, O Schuppan, A Amor, V Kaloutsi: Histologic findings in hone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 64:286-291, 1992.
10. Juvonen E, E Ikkala, K Oksanen, T Ruutu: Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications. Br J Haematol 83:192-197, 1993.
11. Rolovic Z, N Basara, M Gotic, D Sefer, A Bogdanovic: The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 90: 326-331, 1995.
12. Weinfeld A, I Branehög, J Kutti: Platelets in the myeloproliferative syndrome. Clin Haematol 4:373-392, 1975.
13. Rabellino EM, RB Levene, RI, Nachman, LLK Leung: Human megakaryocytes III. Characterization in myeloproliferative disorders. Blood 63:615-622, 1984.
14. Nafe R, A Georgii, V Kaloutsi, RS Fritsch, H Choritz: Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders. Virchows Arch B Cell Pathol Incl Mol Pathol 61:111-116, 1991.
15. Thiele J, S Wagner, R Weuste, D Dienemann, S Wienhold, R Zankovich, R Fischer, H Stein: An immunomorphometric study on megakaryocyte precursor cells in bone marrow tissue from patients with chronic myeloid leukemia (CML). Eur J Haematol 44:63-70, 1990.
16. Kanz L, C Hollen, P Friese, SA Burstein: Analysis of megakaryocyte ploidy in patients with thrombocytosis. Int J Cell Cloning 8:299-306, 1990.
17. Queißer W, G Weidenauer, U Queißer, U Kempgens, U Müller: Megakaryocyte polyploidization in myeloproliferative disorders. Blut 32:13-20, 1976.
18. Jacobsson S, J Carneskog, B Ridell, H Wadenvik, B Swolin, J Kutti: Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol 56:287-292, 1996.
19. Lagerlöf B, S Franzen: The ultrastructure of megakaryocytes in polycythemia vera and chronic granulocytic leukemia. Acta Pathol Microbiol Scand A 80:71-83, 1972.
20. Florensa L, C Besses, S Woessner, F Sole, P Acin, C Pedro, J SansSabrafen: Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia 9:271-273, 1995.
21. Crook M, S Machin, N Crawford: Electrokinetic behaviour and surface sialic acid status of blood platelets in essential thrombocythaemia (ET). Eur J Haematol 49:128-132, 1992.
22. Kobayashi S, M Teramura, S Hoshino, T Motoji, K Oshimi, H Mizoguchi: Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 83:539-544, 1993.
23. Correa PN, D Eskinazi, AA Axelrad. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood 83:99-112, 1994.
24. Martin JM, YK Gandhi, WR Jackson, EN Dessypris: Hypersensitivity of polycythemia vera megakaryocytic progenitors to thrombopoietin. Blood 88 (Suppl 1):94 (Abst), 1996.
25. Li Y, G Hetet, AM Maurer, Y Chait, D Dhermy, J Briere: Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol 87:471-476, 1994.
26. Li Y, G Hetet, JJ Kiladjian, C Gardin, B Grandchamp, J Briere: Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 92: 60-66, 1996.
27. Hehlmann R, H Heimpel, J Hasford, HJ Kolb, H Pralle, DK Hossfeld, W Queisser, H Loffler, A Hochhaus, B Heinze, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077, 1994.
28. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994.
29. Hasselbalch H, BA Jensen: Prognostic factors in idiopathic myelofibrosis: A simple scoring system with prognostic significance. Eur J Haematol 44:172-178, 1990.
30. Pereira A, F Cervantes, R Brugues, C Rozman: Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation. Eur J Haematol 44:94-98, 1990.
31. Zankovich R, J Thiele, B Modder, T Steinberg, K-G Simon, R Fischer, V Diehl: Die sogenannte primäre (idiopathische) Osteomyelofibrose/-sklerose (OMF) im Rahmen chronischer myeloproliferativer Erkrankungen. Med Klin 83:629-636, 1988.
32. Anger B, U Haug, R Seidler, H Heimpel: Polycythemia vera. A clinical study of 141 patients. Blut 59:493-500, 1989.
33. Boivin P: Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 35:491-498, 1993.
34. Rozman C, M Giralt, E Feliu, D Rubio, MT Cortes: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991.
35. Berk PD, LR Wasserman, SM Fruchtman, JD Goldberg: Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, PD Berk, NI Berlin (eds): Polycythemia Vera and the Myeloproliferative Disorders. Saunders, Philadelphia, 1995, pp 166-194.
36. Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664, 1995.
37. 32P between 1969 and 1981. Semin Hematol 34: 6-16, 1997.
38. Cortelazzo S, P Viero, G Finazzi, A D'Emilio, F Rodeghiero,T Barbui: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990.
39. Fenaux P, M Simon, MT Caulier, JL Lai, J Goudemand, F Bauters: Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549-556, 1990.
40. McIntyre KJ, HC Hoagland, MN Silverstein, RM Petitt: Essential thrombocythemia in young adults. Mayo Clin Proc 66:149-154, 1991.
41. Hehlmann R, M Jahn, B Baumann, W Kopeke: Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 61:2487-2496, 1988.
42. Chistolini A, MG Mazzucconi, A Ferrari, G la Verde, G Ferrazza, F Dragoni, A Vitale, R Arcieri, F Mandelli: Essential thrombocythemia: A retrospective study on the clinical course of 100 patients. Haematologica 75:537-540, 1990.
43. Colombi M, F Radaelli, L Zocchi, AT Maiolo: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926-2930, 1991.
44. Barbui T, S Cortelazzo, P Viero, R Bassan, E Dini, N Semeraro: Thrombohemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur J Cancer Clin Oncol 19:1593-1599, 1983.
45. Berk PD, JD Goldberg, MN Silverstein, A Weinfeld, PB Donovan, JT Ellis, SA Landaw, J Laszlo, Y Najean, AV Pisciotta, LR Wasserman: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441-447, 1981.
46. Teofili L, V De Stefano, G Leone, P Micalizzi, MS Iovino, G Alfano, B Bizzi: Hematological causes of venous thrombosis in young people: High incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemostas 67:297-301, 1992.
47. Small BM, RE Bettigole: Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am J Clin Pathol 76:685-691, 1981.
48. Van der Lelie J, AK von dem Borne: Platelet volume analysis for differential diagnosis of thrombocytosis. J Clin Pathol 39:129-133, 1986.
49. Maldonado JE, T Pintado, RV Pierre: Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative disorders: I. The platelets: Ultrastructure and peroxidase reaction. Blood 43:797-809, 1974.
50. Rendu F, M Lebret, A Nurden, JP Caen: Detection of an acquired storage pool deficiency in three patients with a myeloproliferative disorder. Thromb Haemostas 42:794-796, 1979.
51. Caranobe C, P Sie, G Laurent, J Pris, B Boneu: Platelets in myeloproliferative disorders: II. Serotonin uptake and storage: Correlation with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 25:289-295, 1980.
52. Malpass TW, B Savage, SR Hanson, SJ Slichter, LA Harker: Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 103:894-904, 1984.
53. Leoncini G, F Balestrero, M Marcesca, U Armani, A Piana: Platelet lysosomal enzymes are normal in myeloproliferative disorders. Acta Haematol 72:190-194, 1984.
54. Holme S, S Murphy: Studies of the platelet density abnormality in myeloproliferative disease. J Lab Clin Med 103:373-383, 1984.
55. Murphy S, JL Davis, PN Walsh, FH Gardner: Template bleeding time and clinical hemorrhage in myeloproliferative disorders. Arch Intern Med 138:1251-1253, 1978.
56. Boneu B, C Nouvel, P Sie, C Caranobe, D Combes, G Laurent, J Pris, R Bierme: Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests. Scand J Haematol 25:214-220, 1980.
57. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1-12, 1984.
58. Finazzi G, U Budde, JJ Michiels: Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma 22 (Suppl 1)71-78, 1996.
59. Neemeh JA, EJW Bowie, JH Thompson, P Didisheim, CA Owen: Quantitation of platelet aggregation in myeloproliferative disorders. Am J Clin Pathol 57:336-347, 1972.
60. Ginsburg AD: Platelet function in patients with high platelet counts. Ann Intern Med 82:506-511, 1975.
61. Cortelazzo S, P Viero, R Bassan, T Barbui: Spectrum of platelet aggregation abnormalities in myeloproliferative diseases. La Ricerca Clin Lab 11:35-42, 1981.
62. Yamamoto K, E Sekiguchi, O Takatani: Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemostas 52:292-296, 1984.
63. Wehmeier A, RE Scharf, S Fricke, W Schneider: A prospective study of hemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol 45:191-197, 1990.
64. Balduini CL, G Bertolino, P Noris, GC Piletta: Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 95:82-86, 1991.
65. Wu KY: Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 88:7-11, 1978.
66. Saniabadi AR, GDO Lowe, JC Barbenel, CD Forbes: A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: Additional evidence for the role of ADP. Thromb Haemostas 51:115-118, 1984.
67. Boughton BJ, MJ Allington, A King: Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 40:125-132, 1978.
68. Cortelazzo S, P Viero, T Barbui: Platelet activation in myeloproliferative disorders. Thromb Haemostas 45:211-213, 1981.
69. Ireland H, DA Lane, S Wolff, M Foadi: In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 48:41-45, 1982.
70. Najean Y, O Poirier, F Lokiec: The clinical significance of beta-thromboglobulin and platelet factor-4 in polycythaemic patients. Scand J Haematol 31:298-304, 1983.
71. Wehmeier A, RE Scharf, S Fricke, W Schneider: Bleeding and thrombosis in chronic myeloproliferative disorders: Relation of platelet disorders to clinical aspects of the disease. Haemostasis 19:251-259, 1989.
72. Gersuk GM, R Carmel, PK Peltengale: Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 74:2330-2334, 1989.
73. Bernabei PA, A Arcangeli, M Casini, A Grossi, R Padovani, P Rossi Ferrini: Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 63:353-357, 1986.
74. Baglin TP, SM Price, BJ Boughton: A reversible defect of platelet PDGF content in myeloproliferative disorders. Br J Haematol 69:483-486, 1988.
75. Wehmeier A, D Tschope, J Esser, C Menzel, HK Nieuwenhuis, W Schneider: Circulating activated platelets in myeloproliferative disorders. Thromb Res 61:271-278, 1991.
76. Nurden P, C Bihour, M Smith, JM Raymond, AT Nurden: Platelet activation and thrombosis: Studies in a patient with essential thrombocythemia. Am J Hematol 51:79-84, 1996.
77. Okuma M, H Uchino: Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 54:1258-1271, 1979.
78. Russell NH, J Salmon, JP Keenan, AJ Bellingham: Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 22:389-397, 1981.
79. Schafer AI: Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 306:381-386, 1982.
80. Takayama H, M Okuma, K Kanaji, T Sugiyama, S Sensaki, H Uchino: Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders. Prostaglandins Leukotrienes Med 12:261-272, 1983.
81. Smith IL, TJ Martin: Platelet thromboxane synthesis and release reactions in myeloproliferative disorders. Haemostasis 11:119-127, 1982.
82. Zahavi J, M Zahavi, E Firsteter, B Frish, R Turleanu, P Rachmani: An abnormal pattern of multiple platelet function abnormalities and increased thrornboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 47:326-332, 1991.
83. Landoin R, G Ciabattoni, P Patrignani, MA Castellana, E Pogliani, B Bizzi, C Patrono: Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965-1971, 1992.
84. Rocca B, G Ciabattoni, R Tartaglione, S Cortelazzo, T Barbui, C Patrono, R Landolfi: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemostas 74:1225-1230, 1995.
85. Van Genderen PJ, JJ Michiels, FJ Zijlstra: Lipoxygenase deficiency in primary thrombocythemia is not a true deficiency. Thromb Haemostas 71:803-804, 1994.
86. Kaywin P, M McDonough, PA Insel, S Shattil: Platelet function in essential thrombocythemia: Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 299:505-509, 1978.
87. Swart SS, D Pearson, JK Wood, DB Barnett: Functional significance of the alpha-2-adrenoceptor: Studies in patients with myeloproliferative disorders. Thromb Res 33:531-541, 1984.
88. Ushikubi F, M Okuma, T Ishibashi, S Narumiya, H Uchino: Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. Am J Hematol 33:96-100, 1990.
89. 2 in patients with myeloproliferative disorders. Blood 52:618-626, 1978.
90. Cooper B, D Ahem: Characterization of the platelet prostaglandin D, receptor. J Clin Invest 64:586-590, 1979.
91. Cortelazzo S, M Galli, D Castagna, P Viero, G de Gaetano, T Barbui: Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with myeloproliferative disorders. Thromb Haemostas 59:73-76, 1988.
92. Handa M, K Watanabe, Y Kawai, T Kamata, T Koyama, H Nagai, Y Ikeda: Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferalive disorder. Thromb Haemostas 73:521-528, 1995.
93. Gugliotta L, C Pickering, M Greaves, FE Preston: Abnormality of platelet membrane glycoproteins in essential thrombocythemia. Thromb Haemostas 50:216 (Abst), 1983.
94. Mazzucato M, LD Marco, VD Angelis, DD Roia, N Bizzaro, A Casonato: Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 73:369-374, 1989.
95. Eche N, P Sie, C Caranobe, C Nouvel, J Pris, B Boneu: Platelets in myeloproliferative disorders. III: Glycoprotein profile in relation to platelet function and platelet density. Scand J Hematol 26:123-129, 1981.
96. Clezardin P, JL McGregor, M Dechavanne, KL Clemetson: Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br J Haematol 60:331-344, 1985.
97. Landolfi R, R De Cristofaro, M Castagnola, E De Candia, G D'Onofrio, G Leone, B Bizzi: Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood 71:978-982, 1988.
98. 125I-fibrinogen binding to platelets in myeloproliferative disease. Thromb Haemostas 66:329-333, 1991.
99. Legrand C, S Bellucci, M Disdier, L Edelman, G Tobelem: Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: Effect of alpha-interferon treatment. Am J Hematol 38:307-313, 1991.
100. Thihert V, S Bellucci, M Cristofari, E Gluckman, C Legrand: Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol 91:618-624, 1995.
101. Bolin RB, T Okumura, GA Jamieson: Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am J Hematol 3:63-71, 1977.
102. 3H yohimbine in patients with myeloproliferative disorders. Thromb Res 40:623-629, 1985.
103. Swart SS, M Maguire, JK Wood, DB Barnett: Alpha,-adrenoceptor coupling to adenylate cyclase in adrenaline insensitive human platelets. Eur J Pharmacol 116:113-119, 1985.
104. 2+ accumulation into the dense tubular system. Thromb Res 53:99-108, 1989.
105. 2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 57:1801-1804, 1981.
106. 2 receptor in a patient with polycythemia vera. Thromb Haemostas 67:144-146, 1992.
107. Eigenthaler M, H Ullrich, J Geiger, K Horstrup, P Honig-Liedl, D Wiebecke, U Walter: Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem 268:13526-13531, 1993.
108. Cancelas JA, A Garcia-Avello, LJ Garcia-Frade: High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 75:513-520, 1994.
109. Bazzan M, G Tamponi, E Gallo, S Stella, PC Schinco, A Pannocchia, A Pileri: Fibrinolytic imbalance in essential thrombocythemia: Role of platelets. Haemostasis 23:38-44, 1993.
110. Wieczorek I, IR MacGregor, CA Ludlam: Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol 49:277-281, 1995.
111. Bellucci S, E Ignatova, N Jaillet, MC Boffa: Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemostas 70:736-742, 1993.
112. Baker RI, A Manoharan: Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 40:267-272, 1988.
113. Wehmeier A, RE Scharf, W Schneider: Abnormal platelet subpopulations in myeloproliferative disorders in relation to platelet function. In: Barbui T, S Cortelazzo, P Viero, S Gorini, GD Gaetano (eds): Cellular Blood Components in Haemostasis and Thrombosis. John Libbey Eurotext, Paris, 1988, pp 117-121.
114. Stenke L, C Edenius, J Samuelsson, JA Lindgren: Deficient lipoxin synthesis: A novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 78:2989-2995, 1991.
115. Barbui T, R Bassan, P Viero, S Cortelazzo, E Dini: Platelet function after busulfan in chronic myeloproliferative disorders. Haematologica 68:469-477, 1983.
116. Pareti FI, L Gugliotta, L Mannucci, A Guarini, PM Mannucci: Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disease. Thromb Haemostas 47:84-89, 1982.
117. Boughton BJ: Chronic myeloproliferative disorders: Improved platelet aggregation following venesection. Br J Haematol 39: 589-598, 1978.
118. Catani L, L Gugliotta, ML Cascione, M Mattioli Belmonte, N Vianelli, AR Belardinelli, S Tura: Platelet function and interferon alpha-2a treatment in essential thrombocythaemia. Eur J Haematol 46:158-162, 1991.
119. Viero P, S Cortelazzo, R Bassan, T Barbui: Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative disease. Thromb Haemostas 48:125-126, 1982.
120. Najean Y, O Poirier: Beta-thromboglobulin and platelet factor 4 in polycythemia patients treated with ticlopidine. Acta Haematol 72:83-89, 1984.
121. Boneu B: Laboratory investigations and prediction of thrombotic risk in polycythemia vera. Nouv Rev Fr Hematol 36:183-185, 1994.
122. Wehmeier A, I Daum, H Jamin, W Schneider: Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63:101-106, 1991.
123. Lahuerta-Palacios JJ, R Bornstein, FJ Fernandez-Debora, E Gutierrez-Rivas, MC Ortiz, S Larregla, L Calandre, J Montero-Castillo: Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 61:1207-1212, 1988.
124. Cortelazzo S, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, T Barbui: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
125. Chott A, H Gisslinger, J Thiele, E Fritz, W Linkesch, T Radaszkiewicz, H Ludwig: Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 74: 10-16, 1990.
126. Gugliotta L, GP Bagnara, L Catani, L Gaggioli, A Guarini, G Zauli, MM Belmonte, F Lauria, S Macchi, S Tura: In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 71:177-181, 1989.
127. Michiels JJ, J Abels, J Steketee, HHDM vanVliet, VD Vuzevski: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
128. Michiels JJ, PJ Koudstaal, AH Mulder, HH van Vliet: Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
129. Van Genderen PJ, JJ Michiels, R van Strik, J Lindemans, HH van Vliet: Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin. Thromb Haemostas 73:210-214, 1995.
130. Tartaglia AP, JD Goldberg, PD Berk, LR Wasserman: Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172-176, 1986.
131. Weinfeld A, B Swolin, J Westin: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52:134-139, 1994.
132. Nand S, W Stock, J Godwin, SG Fisher: Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 52:42-46, 1996.
133. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 92:69-76, 1992.
134. Spencer CM, RN Brogden: Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 47:809-822, 1994.
135. Silverstein MN: Anagrelide in myeloproliferative diseases. In: Wasserman LR, PD Berk, NI Berlin (eds): Polycythemia Vera and the Myeloproliferative Disorders. Saunders, Philadelphia, 1995, pp 329-336.
136. Silver RT: Interferon in the treatment of myeloproliferative diseases. Semin Hematol 27:6-14, 1990.
137. Gisslinger H, H Ludwig, W Linkesch, A Choit, E Fritz, T Radaszkiewicz: Long-term interferon therapy for thrombocytosis in myeloproliferative disorders. Lancet 1:634-637, 1989.
138. Sacchi S: The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): A concise update. Leuk Lymphoma 19:13-20, 1995.
139. Wehmeier A: Interferon therapy of essential thrombocythemia and polycythemia vera. In: Aul C, W Schneider (eds): Interferons, Biological Activities and Clinical Efficacy. Springer, Berlin, 1997, pp 67-83.
140. Taylor PC, G Dolan, J-P Ng, B Paul, R Collin, JT Reilly: Efficacy of recombinant interteron-alpha (rIFN-α) in polycythemia vera: A study of 17 patienls and an analysis of published data. Br J Haematol 92:55-59, 1996.
141. Sacchi S, A Tabilio, P Leoni, A Riccardi, A Vecchi, C Messora, L Bensi, F Falzetti, S Rupoli, G Ucci: Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment. Ann Hematol 66: 245-246, 1993.
142. Kasparu H, M Bernhart, O Krieger, D Lutz: Remission may continue after termination of rIFN alpha-2h treatment for essential thrombocythemia. Fur J Haematol 48:33-36, 1992.
143. Marmont AM, M Sessarego: Chronic clonal myeloproliferative disease associated with a t(5; 21) translocation. Complete hut transient hematologic and cytogenetic remission induced by interferon-alpha. Leukemia 9:977-980, 1995.
144. Hino M, E Futami, S Okuno, T Miki, Y Nishizawa, H Modi: Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 66:161-162, 1993.
145. Petrini M, P Simi, G Saglio: Cytogenetic remission induced by interferon-alpha in a myeloproliferative disorder with trisomy 8. Br J Haematol 92:941-943, 1996.
146. Lengfelder E, M Griesshammer, R Hehlmann: Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22 (Suppl 1):135-142, 1996.
147. Mason JE, VT DeVita, GP Canellos: Thrombocytosis in chronic granulocytic leukemia: Incidence and clinical significance. Blood 44:483-487, 1974.
148. Wehmeier A, A Popescu, W Schneider: Incidence of bleeding and thrombotic complications increase in advanced stages of chronic myeloid leukemia. A retrospective analysis of 182 patients. Ann Hematol 72 (Suppl I):A24 (Abst), 1996.
149. Pitcock JA, EH Reinhard, BW Justus, RS Mendelsohn: A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med 57:73-84, 1962.
150. Bouroncle BA, CA Doan: Myelofibrosis: Clinical, hematologic and pathologic study of 110 patients. Am J Med Sci 243:697-715, 1962.
151. Silverstein MN, JW Linman: Causes of death in agnogenic myeloid metaplasia. Mayo Clin Proc 44:36-39, 1969.
152. Hasselbalch H: Idiopathic myelofibrosis: A clinical study of 80 patients. Am J Hematol 34:291-300, 1990.
153. Chievitz E, T Thiede: Complications and causes of death in polycythemia vera. Acta Med Scand 172:513-523, 1962.
154. Messinezy M, TC Pearson, A Prochazka, G Wetherley-Mein: Treatment of primary proliferative polycythaemia by venesection and low dose busulfan: Retrospective study from one center. Br J Haematol 61:657-666, 1985.
155. Bellucci S, M Janvier, G Tobelem, G Flandrin, Y Charpak, R Berger, M Boiron: Essential thrombocythemias: Clinical and biological data. Cancer 58:2440-2447, 1986.
156. Wehmeier A, F Meierkord, W Schneider: Vascular complications in essential thrombocythemia - A retrospective analysis of 128 cases. Blood 86 (Suppl I):804 (Abst), 1995.